2seventybio.com - TSVT Enterprise Value-to-Sales Ratio

Public company logo of 2seventy bio Inc. (TSVT)

Partnerships with pharmaceutical behemoths in the field of genetic engineering strengthen the position of 2seventy bio, Inc. (TSVT). The EV/Sales multiple on the GURU.Markets consolidated chart visualizes this resilience, where the value represents the current metric. 2seventy bio, Inc. (TSVT) is penetrating the global CAR-T therapy market for myeloma, while workforce optimization has allowed the company to concentrate resources on supporting key commercial products.

2seventybio.com (TSVT): Enterprise Value-to-Revenue Ratio from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for 2seventy Bio (TSVT)

Fundamental valuation:2seventy bio, Inc. (TSVT)
Core merchandise of 2seventy bio Inc.

This indicator compares the total enterprise value with the volume of generated revenue, excluding the impact of debt load to determine the real market value of assets during a period of high interest rates. By analyzing the enterprise value-to-revenue chart, an investor assesses the investment attractiveness of 2seventy bio, Inc. (TSVT), considering that the high cost of CAR-T therapy patents and strict FDA oversight create a significant barrier to entry for competitors.